Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

61509 1497862462HCLSReviewTaiwanJune2017.pdf
Energy Boardroom

Sobi signs licencing deal for TiGenix's cell-based therapy

03.04.2014 / Scripintelligence

Swedish Orphan Biovitrum (SOBI) has acquired the licensing rights to Belgium-based TiGenix's ChrondroCelet, a cell-based product for the repair of cartilage defects of the knee.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: